Phio Pharmaceuticals (PHIO) Competitors $2.13 -0.05 (-2.29%) Closing price 04:00 PM EasternExtended Trading$2.12 -0.01 (-0.47%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHIO vs. LTRN, PEPG, NBRV, RNXT, ATHE, AADI, ANVS, GRCE, JSPR, and IPSCShould you be buying Phio Pharmaceuticals stock or one of its competitors? The main competitors of Phio Pharmaceuticals include Lantern Pharma (LTRN), PepGen (PEPG), Nabriva Therapeutics (NBRV), RenovoRx (RNXT), Alterity Therapeutics (ATHE), Aadi Bioscience (AADI), Annovis Bio (ANVS), Grace Therapeutics (GRCE), Jasper Therapeutics (JSPR), and Century Therapeutics (IPSC). These companies are all part of the "pharmaceutical products" industry. Phio Pharmaceuticals vs. Its Competitors Lantern Pharma PepGen Nabriva Therapeutics RenovoRx Alterity Therapeutics Aadi Bioscience Annovis Bio Grace Therapeutics Jasper Therapeutics Century Therapeutics Lantern Pharma (NASDAQ:LTRN) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment. Does the media prefer LTRN or PHIO? In the previous week, Phio Pharmaceuticals had 1 more articles in the media than Lantern Pharma. MarketBeat recorded 3 mentions for Phio Pharmaceuticals and 2 mentions for Lantern Pharma. Phio Pharmaceuticals' average media sentiment score of 0.96 beat Lantern Pharma's score of 0.95 indicating that Phio Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantern Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phio Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, LTRN or PHIO? Lantern Pharma has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500. Comparatively, Phio Pharmaceuticals has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Which has higher earnings & valuation, LTRN or PHIO? Lantern Pharma is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLantern PharmaN/AN/A-$20.78M-$1.78-2.14Phio PharmaceuticalsN/AN/A-$7.15M-$3.25-0.66 Is LTRN or PHIO more profitable? Phio Pharmaceuticals' return on equity of -88.75% beat Lantern Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Lantern PharmaN/A -99.89% -81.58% Phio Pharmaceuticals N/A -88.75%-77.98% Do analysts recommend LTRN or PHIO? Lantern Pharma presently has a consensus target price of $25.00, suggesting a potential upside of 556.17%. Phio Pharmaceuticals has a consensus target price of $14.00, suggesting a potential upside of 557.28%. Given Phio Pharmaceuticals' higher probable upside, analysts clearly believe Phio Pharmaceuticals is more favorable than Lantern Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Phio Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals hold more shares of LTRN or PHIO? 28.6% of Lantern Pharma shares are held by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are held by institutional investors. 8.5% of Lantern Pharma shares are held by insiders. Comparatively, 0.9% of Phio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryPhio Pharmaceuticals beats Lantern Pharma on 8 of the 11 factors compared between the two stocks. Get Phio Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHIO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHIO vs. The Competition Export to ExcelMetricPhio PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.48M$2.56B$5.79B$10.18BDividend YieldN/A57.23%5.73%4.61%P/E Ratio-0.6623.2874.8626.40Price / SalesN/A692.88543.29125.95Price / CashN/A27.5625.8129.91Price / Book3.095.4013.256.28Net Income-$7.15M$32.95M$3.29B$270.38M7 Day Performance0.47%0.21%0.47%2.70%1 Month Performance-2.29%4.10%4.60%5.99%1 Year Performance-35.26%-2.91%73.42%25.94% Phio Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHIOPhio Pharmaceuticals2.7813 of 5 stars$2.13-2.3%$14.00+557.3%-33.7%$12.48MN/A-0.6610News CoverageAnalyst UpgradeShort Interest ↓Gap DownLTRNLantern Pharma2.3665 of 5 stars$4.06-5.8%$25.00+515.8%-4.7%$46.54MN/A-2.2820PEPGPepGen2.8266 of 5 stars$1.49+6.4%$7.67+414.5%-84.4%$45.92MN/A-0.5030NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070RNXTRenovoRx2.3481 of 5 stars$1.14-8.1%$7.50+557.9%+13.7%$45.44M$40K-3.006Short Interest ↑Gap UpATHEAlterity Therapeutics2.4898 of 5 stars$5.17+2.0%$12.00+132.1%+287.3%$44.96MN/A0.0010News CoverageGap UpHigh Trading VolumeAADIAadi BioscienceN/A$1.82+0.6%N/A+10.6%$44.95M$25.07M-0.8040ANVSAnnovis Bio2.116 of 5 stars$2.34+2.1%$17.33+641.4%-68.9%$44.62MN/A-1.153GRCEGrace Therapeutics2.9079 of 5 stars$3.24+1.3%$12.00+270.4%N/A$44.25MN/A-3.77N/ANews CoverageAnalyst UpgradeJSPRJasper Therapeutics3.4519 of 5 stars$2.65-2.6%$28.75+984.9%-89.3%$44.21MN/A-0.4420IPSCCentury Therapeutics2.0842 of 5 stars$0.51+1.1%$3.75+634.9%-68.7%$43.60M$6.59M-1.76170Gap Up Related Companies and Tools Related Companies LTRN Competitors PEPG Competitors NBRV Competitors RNXT Competitors ATHE Competitors AADI Competitors ANVS Competitors GRCE Competitors JSPR Competitors IPSC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHIO) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phio Pharmaceuticals Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PHIO Stock Alerts